Advances towards early detection with the aid of philanthropy of The Susan Morrow Legacy Foundation. The Mayo clinic is using high grade technologies and equipment to attack high grade serious ovarian cancers.
The most common and deadly subtype with a vaccine that raises patient’s immune response to a protein called “Folate receptor alpha”. This protein is present in 90% of HGSOC cases that relapse and is not present in most normal tissues.
The first two trials of this therapy have suggested a unique response that involves attacking multiple arms of the immune system and patients tolerate the vaccine well. The next step is Phase II to determine efficacy with more patients who have HGSOC. The Mayo Clinic’s foci continues to be delivery of complex care through scientific discovery.